Grail chief growth officer Andrew Partridge sells $1.15m in stock
GRAIL's Chief Growth Officer Andrew Partridge sold 7,873 shares worth $1.15m at $146.39 each on Oct 5, 2026, to cover taxes. He now holds 155,865 shares. The stock is down from the sale price but up 170% in six months. Analysts have mixed views on its valuation and price targets post-FDA panel approval of its Galleri test.
How this was made
The 30-second read
Why it matters
The insider sale adds a fresh data point for traders assessing short‑term risk, while the positive FDA outlook may support the stock longer term.
Market read
Form 4 filing provides new insider‑sell information; traders may watch for short‑term price pressure.
What to watch
Potential upcoming FDA decisions on the Galleri test could offset the negative sentiment from the insider sale.
Background
Grail (GRAL) is a liquid‑biopsy company whose Galleri multi‑cancer detection test recently received a favorable FDA advisory committee vote.
Ticker impact
Chief Growth Officer Andrew Partridge sold 7,873 shares of Grail (GRAL) for $1.15 million on Oct 5, 2026, a Form 4 insider‑sale filing.
likely pressure as the market prices in the insider sell
Form 4 disclosures are primary source filings; a $1.15 M sale by a top officer is material and can prompt short‑term selling pressure.
Market effects
Minimal; the sale is company‑specific and does not affect the broader biotech sector.
None; the filing is US‑focused and limited to Grail shareholders.
Low; no cross‑border implications.
Counterpoint
The sale could be a routine tax‑related sell‑to‑cover, not a lack of confidence, so the stock may remain stable.
Key entities
- ExecutiveAndrew Partridge
Chief Growth Officer of Grail, seller of 7,873 shares.
- CompanyGrail, Inc.
Biotech firm developing the Galleri early‑cancer detection test.
